The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Trends in 2009: You’ve Got a Friend In…

story yesterday reminded me about a movement I think we’ll start seeing a lot more of — funding to commercial entities by disease advocacy foundations.  This will be fueled in 2009 by two factors:

  • a self-perpetuating availability heuristic that will encourage foundations to seek commercialization opportunities; and
  • an economic environment that will have companies looking harder than ever for non-dilutive financing.

Yesterday’s story was about a $3.7 million financing by the Leukemia & Lymphoma Society (LLS) into a partnership with Celator Pharmaceuticals, Inc. to support Phase 2 development of Celator’s lead product candidate CPX-351 (Cytarabine: Daunorubicin) Liposome Injection for treatment of adults with acute myeloid leukemia (AML).  Take it away, press release:

The partnership is part of LLS’s Therapy Acceleration Program (TAP), which supports private sector and academic-based projects with the goal of advancing investigational therapies with high prospects for providing near-term benefit to patients with blood cancers.

This is similar to the role the Progeria Research Foundation has played in identifying a gene and funding and recruiting patients to a clinical trial  for Hutchinson-Gilford Progeria Syndrome.

These programs are just one approach that I would characterize as being in the middle of a spectrum.  The most direct approach is one entrepreneur taking an idea all the way from the lab to the clinic, like BioMS.  Other projects take a very indirect approach like the Gates/CHVI/Government of Canada project which will provide funding for manufacturing facilities for HIV vaccine development.

8 responses to “Trends in 2009: You’ve Got a Friend In…

  1. Bloke Redman January 24, 2009 at 8:21 am

    Is Gates still committed to the fund? I understand he has started moving his money in a different direction.

  2. Jeremy G January 24, 2009 at 9:08 am

    There have been several public announcements following up on the initial one I linked to, particularly around the UWO/London bid for the manufacturing facility, so I would expect these specific funds are committed; but I don’t have any info on whether the Gates Foundation is planning similar collaborations going forward. Anyone?

  3. Bloke Redman January 24, 2009 at 12:47 pm

    Thanks for helping the redman get ahead man.

    • Jeremy G January 24, 2009 at 9:26 pm

      sweet inauguration reference!

  4. Pingback: Trends, Trends Everywhere: Random Gloating II « The Cross-Border Biotech Blog

  5. Pingback: Trends Update — Nonprofits Funding Commercialization: TB Alliance Splits Development Costs With J&J Sub for TB Drug « The Cross-Border Biotech Blog

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


Get every new post delivered to your Inbox.

Join 128 other followers